Melanoma vaccine - Therion
Latest Information Update: 06 Apr 2022
Price :
$50 *
At a glance
- Originator Therion Biologics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 06 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the adverse events and Cancer therapeutic trials and immunogenicity sections